Compare MTX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTX | GHRS |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2004 | 2021 |
| Metric | MTX | GHRS |
|---|---|---|
| Price | $66.18 | $23.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $82.00 | $41.38 |
| AVG Volume (30 Days) | 135.4K | ★ 172.9K |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,072,600,000.00 | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $53.94 | $12.04 |
| 52 Week High | $84.34 | $31.44 |
| Indicator | MTX | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 33.28 | 26.96 |
| Support Level | $65.81 | $19.75 |
| Resistance Level | $71.05 | $24.66 |
| Average True Range (ATR) | 1.49 | 1.24 |
| MACD | -0.05 | -0.51 |
| Stochastic Oscillator | 10.63 | 7.49 |
Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of its customers' finished products; and The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve its customers' manufacturing processes and projects. The majority of revenue comes from the United States, while it also has its presence in Canada/Latin America, Europe/Africa, and Asia.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.